US Stock MarketDetailed Quotes
KYTX Kyverna Therapeutics
- 7.200
- +0.210+3.00%
Close Sep 13 16:00 ET
- 7.200
- 0.0000.00%
Post 16:01 ET
310.66MMarket Cap-3389P/E (TTM)
7.293High7.010Low244.24KVolume7.040Open6.990Pre Close1.76MTurnover1.47%Turnover RatioLossP/E (Static)43.15MShares35.06052wk High0.93P/B120.06MFloat Cap6.30052wk Low--Dividend TTM16.68MShs Float35.060Historical High--Div YieldTTM4.04%Amplitude6.300Historical Low7.194Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Kyverna Therapeutics Stock Forum
Kyverna's KYV-101 Receives U.S. FDA RMAT Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
Kyverna Therapeutics (KYTX) has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for KYV-101, its autologous CD19 CAR T-cell therapy, in treating refractory stiff-person syndrome. This designation, based on positive clinical outcomes in Germany, allows Kyverna to receive expert guidance on efficient ...
No comment yet